These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 8389448

  • 1. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.
    Moody TW, Zia F, Draoui M, Brenneman DE, Fridkin M, Davidson A, Gozes I.
    Proc Natl Acad Sci U S A; 1993 May 15; 90(10):4345-9. PubMed ID: 8389448
    [Abstract] [Full Text] [Related]

  • 2. (N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines.
    Zia H, Leyton J, Casibang M, Hau V, Brenneman D, Fridkin M, Gozes I, Moody TW.
    Life Sci; 2000 May 15; 66(5):379-87. PubMed ID: 10670826
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system.
    Gozes I, McCune SK, Jacobson L, Warren D, Moody TW, Fridkin M, Brenneman DE.
    J Pharmacol Exp Ther; 1991 Jun 15; 257(3):959-66. PubMed ID: 1646331
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist.
    Zia H, Hida T, Jakowlew S, Birrer M, Gozes Y, Reubi JC, Fridkin M, Gozes I, Moody TW.
    Cancer Res; 1996 Aug 01; 56(15):3486-9. PubMed ID: 8758916
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vitro and in vivo treatment of colon cancer by VIP antagonists.
    Levy A, Gal R, Granoth R, Dreznik Z, Fridkin M, Gozes I.
    Regul Pept; 2002 Nov 15; 109(1-3):127-33. PubMed ID: 12409224
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of vasoactive intestinal peptide on adenosine 3',5'-monophosphate, ornithine decarboxylase, and cell growth in a human colon cell line.
    Yu D, Seitz PK, Selvanayagam P, Rajaraman S, Townsend CM, Cooper CW.
    Endocrinology; 1992 Sep 15; 131(3):1188-94. PubMed ID: 1324153
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of human neuroblastoma growth by a specific VIP antagonist.
    Lilling G, Wollman Y, Goldstein MN, Rubinraut S, Fridkin M, Brenneman DE, Gozes I.
    J Mol Neurosci; 1992 Sep 15; 5(4):231-9. PubMed ID: 7577366
    [Abstract] [Full Text] [Related]

  • 15. VIPhyb, an antagonist of vasoactive intestinal peptide receptor, enhances cellular antiviral immunity in murine cytomegalovirus infected mice.
    Li JM, Darlak KA, Southerland L, Hossain MS, Jaye DL, Josephson CD, Rosenthal H, Waller EK.
    PLoS One; 2013 Sep 15; 8(5):e63381. PubMed ID: 23723978
    [Abstract] [Full Text] [Related]

  • 16. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
    Jiang S, Kopras E, McMichael M, Bell RH, Ulrich CD.
    Cancer Res; 1997 Apr 15; 57(8):1475-80. PubMed ID: 9108448
    [Abstract] [Full Text] [Related]

  • 17. Cloning and expression of the human vasoactive intestinal peptide receptor.
    Sreedharan SP, Robichon A, Peterson KE, Goetzl EJ.
    Proc Natl Acad Sci U S A; 1991 Jun 01; 88(11):4986-90. PubMed ID: 1675791
    [Abstract] [Full Text] [Related]

  • 18. Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation.
    Vacas E, Fernández-Martínez AB, Bajo AM, Sánchez-Chapado M, Schally AV, Prieto JC, Carmena MJ.
    Biochim Biophys Acta; 2012 Oct 01; 1823(10):1676-85. PubMed ID: 22728770
    [Abstract] [Full Text] [Related]

  • 19. A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes.
    Gozes Y, Brenneman DE, Fridkin M, Asofsky R, Gozes I.
    Brain Res; 1991 Feb 01; 540(1-2):319-21. PubMed ID: 1647246
    [Abstract] [Full Text] [Related]

  • 20. (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
    Moody TW, Jensen RT, Fridkin M, Gozes I.
    J Mol Neurosci; 2002 Feb 01; 18(1-2):29-35. PubMed ID: 11931347
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.